Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Net Income (2016 - 2025)

Adma Biologics (ADMA) has disclosed Net Income for 13 consecutive years, with $60.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income fell 46.02% year-over-year to $60.4 million, compared with a TTM value of $158.0 million through Dec 2025, down 20.1%, and an annual FY2025 reading of $158.0 million, down 20.1% over the prior year.
  • Net Income was $60.4 million for Q4 2025 at Adma Biologics, up from $36.4 million in the prior quarter.
  • Across five years, Net Income topped out at $111.9 million in Q4 2024 and bottomed at -$18.8 million in Q2 2021.
  • Average Net Income over 5 years is $11.3 million, with a median of -$1.9 million recorded in 2023.
  • The sharpest move saw Net Income soared 1299.96% in 2024, then crashed 46.02% in 2025.
  • Year by year, Net Income stood at -$16.5 million in 2021, then rose by 28.55% to -$11.8 million in 2022, then skyrocketed by 189.84% to $10.6 million in 2023, then skyrocketed by 956.12% to $111.9 million in 2024, then plummeted by 46.02% to $60.4 million in 2025.
  • Business Quant data shows Net Income for ADMA at $60.4 million in Q4 2025, $36.4 million in Q3 2025, and $34.2 million in Q2 2025.